Clinical trials: Lung Diseases, Obstructive
Asthma
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
The purpose of this study is to provide safety and tolerability, pharmacokinetics and immunogenicity data for multiple CSJ117 doses inhaled once daily compared with placebo, in adult asthma participants treated with medium or…
- Trial name
- NCT04946318
- Testing
- CSJ117
- Where
- 58 sites in United States, Argentina and 12 more
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma
The primary objective of this trial is to evaluate the safety and efficacy of two doses of tiotropium inhalation solution delivered via the Respimat® inhaler once daily in the afternoon in patients (1 to 5 years old) with…
- Trial name
- NCT01634113
- Testing
- tiotropium-bromide
- Where
- 33 sites in United States, Belgium and 9 more
- Volunteers
- 102 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices
This is a randomised, open-label, placebo, crossover, multicentre study with a single visit. The study will comprise five sub-studies.
- Trial name
- NCT02184624
- Testing
- ELLIPTA, DISKUS/ACCUHALER, MDI
- Where
- 8 sites in Netherlands, United Kingdom
- Volunteers
- 569 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
The objective of this study is to assess the daily variation in bronchodilator response to an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting anticholinergic (ipratropium) individually and…
- Trial name
- NCT01691482
- Testing
- Albuterol/salbutamol, Ipratropium
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Respiratory Hypersensitivity
Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma
The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.
- Trial name
- NCT00263640
- Testing
- Acaroid
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Allergopharma GmbH & Co. KG
Chronic Obstructive Pulmonary Disease
A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.
- Trial name
- NCT01168310
- Testing
- Fluticasone Propionate/Formoterol Fumarate, Formoterol Fumarate
- Where
- 23 sites in United States
- Volunteers
- 468 people
- Sponsor
- Dey
Asthma
Arnuity® Ellipta® Drug Use Investigation
The aim of this post-marketing investigation is to collect and assess the information about safety and effectiveness of ARNUITY® ELLIPTA® (hereinafter referred to as "Arnuity") in daily clinical practice.
- Trial name
- NCT03184480
- Testing
- Arnuity Ellipta
- Where
- 2 sites in Japan
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Study of Danirixin in Japanese Healthy Elderly Male Subjects
Danirixin is a selective chemokine receptor antagonist being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03136380
- Testing
- GSK1325756H
- Where
- 2 sites in Japan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Long-term Safety Study of QVM149 in Japanese Patients With Asthma
The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.
- Trial name
- NCT03100825
- Testing
- QVM149
- Where
- 25 sites in Japan
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Succinate Salt Version of GSK961081 for Healthy Volunteers
Salt Bridging study for GSK961081
- Trial name
- NCT00550225
- Testing
- GSK961081
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Asthma
Vivatmo proTM EU-study: FeNO Monitoring in Asthmatic Patients Responding to ICS Treatment
This is a multi-center study to evaluate fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro in adult and pediatric subjects.
- Trial name
- NCT05553379
- Testing
- FeNO measurement
- Where
- 5 sites in Czechia, Germany
- Volunteers
- 48 people
- Sponsor
- Bosch Healthcare Solutions GmbH
Pulmonary Disease, Chronic Obstructive
Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
This is a multi-center, randomized, double-blind, parallel-group study. The FF/VI inhalation powder once daily and VI inhalation powder once daily will be evaluated in subjects with COPD over 156 weeks.
- Trial name
- NCT01957150
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 45 sites in United States, Canada and 3 more
- Volunteers
- 283 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will assess the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist (SABA)…
- Trial name
- NCT02104674
- Testing
- Lebrikizumab, Montelukast
- Where
- 82 sites in United States, Brazil and 9 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
COPD
Impact of Ibis on Patients With Advanced COPD
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients with COPD.
- Trial name
- NCT03131622
- Testing
- Digital Therapeutics
- Volunteers
- 240 people
- Sponsor
- Senscio Systems
Asthma
Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function
The proposed study is designed to investigate the pharmacokinetics, pharmacodynamics (as measured by serum cortisol) and safety of GW685698X in subjects with moderate hepatic impairment and in healthy subjects following a single…
- Trial name
- NCT00419237
- Testing
- GW685698X
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
- Trial name
- NCT00683722
- Testing
- Prochymal™
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- Mesoblast, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
- Trial name
- NCT02518139
- Testing
- TD-4208, Tiotropium
- Where
- United States
- Volunteers
- 1,060 people
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population
Reports suggest that the Medicaid population includes a higher percentage of smokers than the general population. A high prevalence of smokers in a population is likely to lead to a higher burden of chronic obstructive pulmonary…
- Trial name
- NCT01615783
- Testing
- Subjects with COPD, Subjects without COPD
- Volunteers
- 40,884 people
- Sponsor
- GlaxoSmithKline
Asthma
Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma
The purpose of this study is to compare the safety and tolerability of levalbuterol HFA metered dose inhaler (MDI) versus racemic albuterol HFA MDI in pediatric subjects 4-11 years of age with asthma
- Trial name
- NCT00684866
- Testing
- Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sumitomo Pharma America, Inc.
COPD
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the dose response relationship among four doses of indacaterol as well as placebo delivered via the TWISTHALER® device.
- Trial name
- NCT00557466
- Testing
- indacaterol, formoterol, short acting β2- agonist
- Where
- 75 sites in Argentina, Belgium and 15 more
- Volunteers
- 568 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.